MedTrace Logo

LDR vs. HDR Brachytherapy for Prostate Cancer

NCT03426748 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-01-29

No results posted yet for this study

Summary

H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103

Conditions

Interventions

RADIATION

Low dose rate prostate brachytherapy

Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance

RADIATION

High dose rate prostate brachytherapy

Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate

Sponsors & Collaborators

  • BC Cancer Foundation

    collaborator OTHER

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Ross Halperin, MD · British Columbia Cancer Agency Program Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2026-08-31
Completion
2034-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426748 on ClinicalTrials.gov